Eight-year-old Namibian female cheetah Nabha dies following injury at Kuno National Park
The cheetah was reportedly injured during a possible hunting attempt inside a soft-release boma (enclosure) at KNP. Despite undergoing treatment, she succumbed to her injuries, the statement said.
A soft release boma is an enclosure used in wildlife conservation, particularly for reintroducing animals into the wild. "Nabha, an 8-year-old Namibian female cheetah, died today. She got badly injured a week back, probably during a hunting attempt inside her Soft Release Boma. She had fractures in both the Ulna and the Fibula on the left side, along with other injuries. She was under treatment for a week but succumbed to her injuries. Further details will be known after the post-mortem report is received," the release read.
Cheetahs hunt in the grasslands of Kuno
According to the KNP authorities, the park currently has 26 cheetahs — nine adults (six females and three males) and 17 Indian-born cubs — all of whom are reported to be healthy and doing well.
Additionally, two male cheetahs housed in Gandhisagar are also stated to be in good health. Of the 26 cheetahs at Kuno, 16 are in the wild and have reportedly adapted well to the habitat. They are co-existing with other predators and are regularly hunting.
"Recently, anti-ecto-parasitic medication for all cheetahs has been completed. Two mothers, Veera and Nirva, along with their recently born cubs, are healthy and doing well," the statement added.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
31 minutes ago
- Economic Times
Of samosas, sins and the spiral of shame
Where there's pleasure, there's guilt - and the tantalising matter of guilty pleasures. So, in a grand mai-baap effort to rescue the Indian conscience from its own stomach, a new government directive is in the works that will ensure that samosas and jalebis - those golden, oily icons of joy - come branded with health warnings . The strategy is to guilt out the imbiber of the two greatest desi snacks - at least so that she or he at least goes easy on them. But by informing us of guilt, will the guilty pleasure now become more pleasurable?With every warning with a samosa, will we be nudged back into the comforting embrace of shame eating? Like Victorian England's obsession with corsets and celery sticks, we are now expected to nibble our sin-snacks with penitent faces, a gulp of guilt for every crunchy bite. The logic is simple: if smoking can be seen by smokers as 'cool' despite a warning, why not samosas? Nothing will say 'I'm a rebel' like a woman tearing into a jalebi. Soon, street vendors might shout 'Dilli-style, high cholesterol guaranteed!' to entice the hipster crowd, while aunties debate whether homemade ghee makes shame less commercial. Next up: warning labels on laddoos, followed by therapists offering post-snack guilt counselling. India, it seems, is finally eating its feelings - responsibly.
Mint
2 hours ago
- Mint
Sacrifices, trade-offs behind big win, says Glenmark's Saldanha
The road to drug discovery is long, arduous and littered with failure, but the payoff at the end makes it worth the trouble. It's a lesson that India's best pharmaceutical entrepreneurs knew all along. Yet, it took a Glenn Saldanha to prove it. 'We were always resilient in how we approached innovation. I think that's what finally rewarded us," Saldanha, chief executive officer and managing director of Glenmark Pharmaceuticals Ltd, told Mint in an exclusive interview. He was referring to one of the largest deals for an Indian biopharma firm after Glenmark's US-based unit Ichnos Glenmark Innovation (IGI) secured a $700-million exclusive licensing agreement with AbbVie for its blood cancer drug candidate last week. AbbVie will also pay as much as $1.23 billion as various milestones are completed, as well as tiered, double-digit royalties on net sales. ISB 2001, the investigational drug to treat multiple myeloma, is in phase-1 clinical trials and has shown promising data. In a trial with 35 patients who had exhausted all existing lines of therapy unsuccessfully, 79% showed a clinical response to it, and 30% were cancer-free. 'I hope this acts as a catalyst to expanding the innovation landscape in India…we've demonstrated that you can do it," said Saldanha. Last bet ISB 2001, developed on IGI's proprietary BEAT platform, was the firm's last bet. 'There was no plan B," said Saldanha. 'This was pretty much the end of the road. At this point, the technology had to demonstrate that it worked…or we don't know what we would have done as the next thing." The drug had been in discovery over the last five years, while the company had been working on the BEAT platform for about a decade. There were three other assets that the company stopped developing. ISB 2001 has received both the US FDA Orphan Drug and Fast Track designations, highlighting its Orphan Drug designation is given to drugs treating rare diseases, while a fast track designation intends to expedite the development and review of drugs for treating serious conditions and fill unmet medical needs. Following the licensing agreement, AbbVie will take over further development for phase-2 and phase-3 trials before it can file for regulatory approval. The process would typically take four to five years. The market size for multiple myeloma is estimated to grow to $50 billion by 2030. Should the drug hit the markets in 2030, taking into account the tiered double-digit royalties, Glenmark stands to earn an additional $2.02 billion in royalties until 2041, according to research by brokerage Nuvama. The deal validates several aspects of Glenmark, including the strength of IGI's BEAT platform, the potential for ISB 2001 to treat relapsed/refractory multiple myeloma, and its commercial viability following successful clinical trials, said an 11 July note by Motilal Oswal analysts. 'Moreover, AbbVie has established itself as a diversified biopharma leader, combining scientific innovation with strong commercial execution. In oncology, the company has built a robust presence anchored by two cornerstone therapies: Imbruvica, a BTK inhibitor, and Venclexta, a BCL-2 inhibitor. These medicines have transformed the treatment landscape for chronic lymphocytic leukemia and other B-cell malignancies, generating multi-billion-dollar revenues and reinforcing AbbVie's reputation as a pioneer in hematologic cancer," the note added. Huge sacrifices, trade-offs Saldanha has bet on innovation since he took the reins of the company in the late 90s. A few years after Glenmark was listed in 2000, it established its first R&D centre for novel biologics research in Switzerland. Over the years, the company did a number of licensing deals with novel assets. In 2019, it spun off its R&D entity under a new company, Ichnos Sciences, which built on its proprietary BEAT bispecific platform. The two announced the creation of Ichnos Glenmark Innovation (IGI) in 2024. The company's focus on innovation created a lot of frustration for investors and stakeholders, Saldanha said. '[We were] bordering on being called eccentric," he said. The company also had to sell its stake in its active pharmaceutical ingredient (API) division, Glenmark Life Sciences, to pare its debt in 2023, which was approximately ₹4,500-4,600 crore. Glenmark sold 75% stake in the unit to industrial conglomerate Nirma for ₹5,650 crore. The company has made 'huge sacrifices, huge trade-offs," said Saldanha. With the GLS sale, the company had a choice to decide 'which end of the value chain we play", said Saldanha. 'Whether we play on this API stable end of the value chain, and generate revenues like that, or we play on the high end of the value chain, which is innovation." But innovation is not a cost game, he said. 'It's all about being able to understand where the therapy is going and how to come up with solutions." What's next for Glenmark? IGI spends about $70 million annually on new drug research. With the upfront payment it receives, it will be self-funded for the next three to four years, said Saldanha. The company will also look at rewarding shareholders with dividends. Apart from that, there are no immediate investment plans, said Saldanha. 'At least for the next year or two, we won't do anything. We'll just continue regrouping and trying to figure out strategically where we can further add value," he said. The deal is a big event for the company, which 'basically resets the whole agenda for the company", he said. 'We have to really reset and rethink how we want to see the company over the next five to ten years." ISB 2001's early success has validated the BEAT platform. 'We think we've now got it right with the technology…the idea is how can we exploit that technology much more effectively to add more products and do more," said Saldanha. The unit has another asset called ISB 2301, which is in late pre-clinical development and will go to the clinic next year. This drug will target solid tumours, said Saldanha. IGI also has a couple of other early-stage programs. '...over the next three, four years, we will exploit the technology as effectively as possible."
NDTV
2 hours ago
- NDTV
Samosa, Jalebi And Other Indian Snacks To Carry Health Warnings: "A Big Step To Tackle India's Obesity Crisis," Says Expert
After cigarettes, delicious Indian snacks like samosa, vadapav, kachori and jalebi will soon carry health warnings. As an initiative to promote healthy eating and lifestyle to combat obesity and non-communicable diseases, the Union Health Ministry has urged all ministries, departments and autonomous bodies to display warnings on Indian snacks. The ministry has urged to display oil and sugar content of these food items. It has also called for printing health messages on all official stationeries such as letterheads, envelopes, notepads, folders, etc and publications to reinforce daily reminders on fighting obesity. Are samosas, jalebis and vadapavs harmful? Obesity is a serious yet preventable health condition. This lifestyle disorder can be reversed and prevented with proactive measures that majorly focus on diet and lifestyle interventions. "Foods like jalebis have a very high glycemic index and can spike up your blood sugars without providing any nutritional value. Not just obesity, heavy consumption of these foods can increase the risk of serious health conditions like diabetes, high blood pressure, high cholesterol and much more," Dr. Sameer Gupta, Senior Cardiologist, Group Cardiac Cath Lab Director at Metro Hospitals. "Additionally, foods like samosas and vadapavs are high in trans fat, which can cause inflammation and lead to arterial blockage by contributing to plaque buildup in arteries," Dr. Gupta added. Will these warnings actually help? "The tsunami of obesity, diabetes and high blood pressure in this country mainly because of poor eating habits needs to be controlled with such health policies." "This initiative will empower the common people about the nutritional value of food and help them make conscious food choices," Dr. Gupta highlighted. How will this be put into effect? The information posters will mention fat and sugar content in popular foods. This clear information about sugar and trans fat content will function like health warning labels on cigarettes. "Oil and Sugar Board" in schools, offices, public institutions, autonomous bodies and other organisations displaying key information about hidden fats and sugars in everyday foods can help raise awareness on harmful consumption. Health messages that outline long-term health risks from frequent consumption of these foods will also be implemented. This initiative has also urged organisations and institutions to promote the availability of healthier food options and limit accessibility of sugary drinks and high-fat snacks. It also highlights the role of physical activity. India's obesity burden A sharp rise in obesity rates in India over the past few years is now a significant public health concern. Obesity has serious health implications, fueling non-communicable diseases such as diabetes, heart disease, mobility, quality of life and certain cancers. According to the National Family Health Survey NFHS-5 (2019-21), more than one in five adults in urban areas are overweight or obese. While 24% of Indian women and 23% of Indian men are overweight or obese, a significant increase in the percentage of children under 5 years who are overweight has also been observed from 2.1% to 3.4 %. A Lancet study published in 2025 also revealed that about 450 million adults in India are expected to be overweight or obese in 2050. Addressing these challenges requires a multi-faceted approach, including better public health policies, promoting physical activity, improving access to healthy foods, and increasing awareness about nutritional intake and healthy lifestyles. In the 119th Episode of Mann Ki Baat, Prime Minister Narendra Modi also urged the country to draw focus on the obesity epidemic and mentioned that obesity cases have doubled in the last few years and there is an urgent need to focus on the prevalence of obesity in India. He urged people to reduce their cooking oil consumption by 10 per cent. Advocating the same, Dr. Sameer Gupta who is also the Co-Chair of the Healthcare community at PHD Chamber of Commerce adds, "India is the diabetes capital of the world. Furthermore, an alarming increase in obesity and hypertensive individuals triggers the disease burden of the country. These food labels will empower people to make the right food choices. It is a very good and much-needed step towards a fitter India." "You cannot be a wealthy nation if you are not a healthy nation," he concluded.
